News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
115 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39672)
2015 (44432)
2016 (38329)
2017 (37188)
2018 (39119)
2019 (51334)
2020 (57663)
2021 (58720)
2022 (53928)
2023 (42564)
2024 (37441)
2025 (33090)
2026 (21247)
Month
January (2433)
February (2866)
March (3029)
April (3115)
May (3356)
June (2725)
July (2286)
August (1437)
Day
1 (121)
2 (96)
3 (8)
5 (6)
6 (79)
7 (151)
8 (89)
9 (80)
10 (30)
13 (139)
14 (106)
15 (102)
16 (135)
17 (48)
19 (25)
20 (83)
21 (88)
22 (115)
23 (109)
24 (78)
26 (5)
27 (123)
28 (100)
29 (166)
30 (163)
31 (41)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Month
January
February
March
April
May
June
July
August
Day
1
2
3
5
6
7
8
9
10
13
14
15
16
17
19
20
21
22
23
24
26
27
28
29
30
31
Manufacturing
Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely on
Top-selling cell therapies from BMS, J&J and Gilead depend on a BioLife product, positioning Repligen to use the takeover to increase its exposure to the modality.
July 22, 2026
·
2 min read
·
Nick Paul Taylor
Rare diseases
Arrowhead puts pressure on Ionis with positive data for triglyceride lowering drug
With Phase 3 data showing what analysts called a “potentially best-in-class profile,” Arrowhead Pharmaceuticals plans to submit for FDA approval of plozasiran by the end of the year—hoping to follow to market Ionis Pharmaceuticals’ Tryngolza, which got the regulator’s nod in severe hypertriglyceridemia last month.
July 22, 2026
·
2 min read
·
Heather McKenzie
Press Releases
From Near-Catatonic to Dancing: Advanced Alzheimer’s Patient Experiences Remarkable Functional Turnaround with young Fresh Frozen Plasma (yFFP)
July 22, 2026
·
3 min read
Press Releases
Lilly confirms date and conference call for second-quarter 2026 financial results announcement
July 22, 2026
·
2 min read
Press Releases
Phlow Corp. Appoints Sripathy Venkatraman, Ph.D, As Chief Scientific Officer
July 22, 2026
·
3 min read
Lung cancer
Summit and Akeso sharpen case for ivonescimab with new Western data
Summit Therapeutics and Akeso are answering questions raised about ivonescimab’s ability to translate to Western populations, though the partners have yet to share if the new findings are statistically significant.
July 22, 2026
·
2 min read
·
Gabrielle Masson
Press Releases
L7 Informatics Challenges the Notion of the “AI Governance Layer” in Pharma
July 22, 2026
·
1 min read
Press Releases
FDA Takes Further Steps to Remove Outdated Authorizations for Color Additives in Food
July 22, 2026
·
2 min read
Press Releases
Eurofins Viracor Launches BKV inSIGHT™ T-Cell Immunity Panel to Support BK Virus Immune Monitoring in Kidney Transplant Patients
July 22, 2026
·
3 min read
Press Releases
Valneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026
July 22, 2026
·
3 min read
Previous
11 of 12
Next
